The first 60 days: BRAF V600E-mutant non-small-cell lung cancer
BRAF V600E lung cancer carries the same mutation as many melanomas and is treated with the same pairs of pills that block BRAF and MEK together. Dabrafenib with trametinib and encorafenib with binimetinib each shrink about two thirds to three quarters of untreated tumours. Below, week by week, is what OnCo's record of BRAF V600E-mutant non-small-cell lung cancer says about the first two months: the order is typical, the timing is yours to ask about. Sections appear only where the record has something to say. Orientation, not medical advice.
What happens now
Staging tests establish exactly what and where the cancer is. Everything else follows from the answers.
Ask which of these were tested and what the results were; see the report reader for what each value means.
These specialties appear in the standard of care for this cancer. In most centres they meet weekly as a tumour board to agree each plan; you can ask when yours was discussed and what was decided.
A second opinion from a centre that treats many similar cases is normal, not rude; the standard of care tells you what to compare it against.
Each row is a setting from the standard of care, in the order it usually arises. Not all will apply to you; your stage and biomarkers decide which do. The guideline grade, where recorded, says how strong the evidence is.
Dabrafenib plus trametinib or encorafenib plus binimetinib (PHAROS); pembrolizumab with platinum doublet is an alternative, particularly with high PD-L1.
Pembrolizumab plus platinum doublet, or the other BRAF plus MEK pair if the first was stopped for toxicity rather than progression.
Treated as driver-negative disease with chemoimmunotherapy; MEK or pan-RAF inhibitor trials.
Generated from this cancer's standard of care, biomarkers and open problems. Take the group that matches where you are. To tick, add your own and print, open the one-page appointment sheet.
Newly diagnosed
- What is my exact diagnosis, stage, and grade, and which tests established them?Everything else follows from an accurate stage and subtype.
- Which biomarkers have been tested on my tumour (for example BRAF V600E by sequencing, BRAF mutation class, PD-L1 tumour proportion score, Left ventricular function, eye examination and temperature on BRAF plus MEK inhibitors), and what were the results?These results decide eligibility for targeted therapy, immunotherapy, and trials.
- Which subtype is my cancer, and does that change the recommended treatment?Recognised subtypes for this cancer include BRAF V600E adenocarcinoma, treatment-naive, BRAF V600E adenocarcinoma after chemotherapy or immunotherapy, Non-V600 BRAF mutations, class II and III.
- Is germline (inherited) genetic testing recommended for me or my family?Inherited variants can change treatment and matter for relatives.
Advanced BRAF V600E, first line
- For my situation (advanced braf v600e, first line), which of the standard options do you recommend and why?Guideline options include: Dabrafenib plus trametinib or encorafenib plus binimetinib (PHAROS); pembrolizumab with platinum doublet is an alternative, particularly with high PD-L1.
- Am I a candidate for Dabrafenib + trametinib, Dabrafenib, Trametinib or related drugs, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of PHAROS apply to someone like me?Trial populations differ from individual patients; ask how closely you match.
Advanced BRAF V600E, after targeted therapy
- For my situation (advanced braf v600e, after targeted therapy), which of the standard options do you recommend and why?Guideline options include: Pembrolizumab plus platinum doublet, or the other BRAF plus MEK pair if the first was stopped for toxicity rather than progression.
- Am I a candidate for Pembrolizumab, Carboplatin, Pemetrexed or related drugs, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
Non-V600 BRAF mutations
- For my situation (non-v600 braf mutations), which of the standard options do you recommend and why?Guideline options include: Treated as driver-negative disease with chemoimmunotherapy; MEK or pan-RAF inhibitor trials.
- Am I a candidate for Pembrolizumab, Carboplatin, Pemetrexed or related drugs, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
Any stage
- Are there clinical trials I could join, for example of PHAROS, Encorafenib, Binimetinib?Trials are how the next standard of care is set; asking early keeps options open.
- Would a second opinion at a high-volume centre change anything, and can you help arrange it?Rare or high-stakes decisions benefit from a centre that treats many similar patients.
- What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?Supportive care improves quality of life and helps patients complete treatment.
- I read that “No randomised trial compares BRAF plus MEK inhibitors with chemoimmunotherapy first line or settles the sequence”. How does that affect my plan?Open problems are where trials and second opinions matter most.
- I read that “Non-V600 BRAF mutations, half of cases, have no approved targeted therapy”. How does that affect my plan?Open problems are where trials and second opinions matter most.
Much of what helps in the first weeks is free if you know to ask: testing, helplines, rides and lodging, second opinions, trial travel.
- BRAF V600E-mutant non-small-cell lung cancer: the full pageBRAF V600E lung cancer carries the same mutation as many melanomas and is treated with the same pairs of pills that block BRAF and MEK together. Dabrafenib with trametinib and encorafenib with binimetinib each shrink about two thirds to three quarters of untreated tumours.
- One-page appointment sheetYour questions, the words you may hear, what to bring, and space for the answers. Print it.
- Treatment sequencingWhich treatment tends to follow which, line by line.
- NavigatorStandard of care for your stage, what you have tried, and trials near you.
- Tumour proportion score (TPS): The PD-L1 score used in lung cancer: the percentage of tumour cells that stain positive.
- Driver mutation: One of the few mutations in a tumour that actually causes it to grow.
- BRAF V600E mutation: A single spelling change in the BRAF gene that jams a growth switch permanently on.
- Drug resistance (primary and acquired): Why cancer drugs stop working: the tumour either never depended on the target or evolves around the block.
Every term links to the glossary.